Zai Lab Limited

Zai Lab Limited is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Zai Lab Limited is not a good growth stock. Zai Lab Limited is not very popular among insiders. Zai Lab Limited is a mediocre stock to choose.
Log in to see more information.
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commerc...
ZLAB Fundamental Data by TradingView

News

Zai Lab Limited (NASDAQ:ZLAB) Stock Position Raised by TD Asset Management Inc
Zai Lab Limited (NASDAQ:ZLAB) Stock Position Raised by TD Asset Management Inc

Ticker Report TD Asset Management Inc lifted its position in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 1.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The...\n more…

Analyzing Zai Lab (NASDAQ:ZLAB) and Karyopharm Therapeutics (NASDAQ:KPTI)
Analyzing Zai Lab (NASDAQ:ZLAB) and Karyopharm Therapeutics (NASDAQ:KPTI)

Ticker Report Zai Lab (NASDAQ:ZLAB - Get Free Report) and Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two...\n more…

Zai Lab announced data from Phase 1 study of ZL-1218
Zai Lab announced data from Phase 1 study of ZL-1218

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024

Business Wire Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the companys anti-CCR8 antibody, will be presented in a poster session at the European Society...\n more…

Zai Lab's Revenue Soars, Losses Narrow in Interim Report
Zai Lab's Revenue Soars, Losses Narrow in Interim Report

TipRanks Financial Blog Zai Lab Ltd (HK:9688) has released an update. Zai Lab Limited has reported a significant 42% increase in net product revenue, reaching $187.3 million, largely due t...\n more…

Zai Lab Announces Participation in September Investor Conferences
Zai Lab Announces Participation in September Investor Conferences

Business Wire Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Companys senior management team will participate in the following investor conferences in September 2024: Morgan Stanley...\n more…